ESR1 and neoplasm: Furthermore, these studies employed a range of tumor-agnostic, single-nucleotide variant (SNV)-based ctDNA methodologies, including next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) of gene alterations of interest (e.g., PIK3CA, ESR1) with varying sensitivities that may depend on tumor genotypes7.